Showing results (131-140 of 167) with videos related to

Sort By:
Pageof 17
Lung|February 22, 2023
Canadian Health Care Professionals' Familiarity with Chronic Cough Guidelines and Experiences with Diagnosis and Management: A Cross-Sectional SurveyElena Kum, Danica Brister, Nermin Diab, et al.
ERJ Open Research|March 17, 2018
Research highlights from the 2017 ERS International Congress: airway diseases in focusCecilia Andersson, Sara J Bonvini, Peter Horvath, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 15, 2022
Demographic, clinical, and patient-reported outcome data from 2 global, phase 3 trials of chronic coughPeter V Dicpinigaitis, Surinder S Birring, Michael Blaiss, et al.
Lung|July 27, 2022
Improvements in Objective and Subjective Measures of Chronic Cough with Gefapixant: A Pooled Phase 3 Efficacy Analysis of Predefined SubgroupsJaclyn A Smith, Surinder S Birring, Peter V Dicpinigaitis, et al.
American Journal of Respiratory and Critical Care Medicine|January 16, 2016
Stretch-induced Activation of Transforming Growth Factor-β1 in Pulmonary FibrosisAaron R Froese, Chiko Shimbori, Pierre-Simon Bellaye, et al.
Allergy|December 4, 2022
Sounding the alarmins-The role of alarmin cytokines in asthmaGail M Gauvreau, Celine Bergeron, Louis-Philippe Boulet, et al.
The European Respiratory Journal|November 6, 2025
Mepolizumab for the treatment of refractory chronic cough in patients with eosinophilic airways disease (MUCOSA): a randomized, double-blind, parallel-group, placebo-controlled trialNermin Diab, Danica Brister, Elena Kum, et al.
The European Respiratory Journal|March 14, 2020
The importance of interventional timing in the bleomycin model of pulmonary fibrosisPhilipp Kolb, Chandak Upagupta, Megan Vierhout, et al.
Journal of Translational Medicine|April 12, 2008
Comparison between conventional and "clinical" assessment of experimental lung fibrosisKjetil Ask, Renee Labiris, Laszlo Farkas, et al.
The Journal of Clinical Investigation|February 3, 2004
TNF-alpha is a critical negative regulator of type 1 immune activation during intracellular bacterial infectionAnna Zganiacz, Michael Santosuosso, Jun Wang, et al.
Pageof 17